LipoScience Company Profile (NASDAQ:LPDX)

About LipoScience

LipoScience logoLipoScience, Inc. is a vitro diagnostic company. The Company's diagnostic test, the nuclear magnetic resonance (NMR) LipoProfile test, directly measures the number of low density lipoprotein (LDL), particles in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. The Company's Vantera system is the Company's automated clinical analyzer. As of January 25, 2013, over eight million NMR LipoProfile tests were ordered. The Vantera system is its automated clinical analyzer. In August 2012, the Company received Food and Drug Administration (FDA) clearance to market the Vantera system commercially to laboratories.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: LPDX
  • CUSIP: 53630M10
Key Metrics:
  • Previous Close: $0.00
  • 50 Day Moving Average: $0
  • 200 Day Moving Average: $5
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.24
  • P/E Growth: 0
  • Market Cap: $N/A
Additional Links:
Companies Related to LipoScience:

Analyst Ratings

Consensus Ratings for LipoScience (NASDAQ:LPDX) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for LipoScience (NASDAQ:LPDX)
No equities research coverage for this company has been tracked by


Earnings History for LipoScience (NASDAQ:LPDX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/12/2014Q3 14($0.26)($0.28)ViewN/AView Earnings Details
8/12/2014($0.24)($0.27)ViewN/AView Earnings Details
5/12/2014Q1 14($0.19)($0.13)ViewN/AView Earnings Details
3/10/2014Q413($0.24)($0.17)$12.71 million$12.72 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for LipoScience (NASDAQ:LPDX)
Current Year EPS Consensus Estimate: $-0.93 EPS
Next Year EPS Consensus Estimate: $-0.84 EPS


Dividend History for LipoScience (NASDAQ:LPDX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for LipoScience (NASDAQ:LPDX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/4/2013Daniel LevangieDirectorBuy10,000$4.17$41,700.00View SEC Filing  
12/4/2013E. Duffy McdonaldVPSell12,731$4.07$51,815.17View SEC Filing  
11/25/2013James HurleyDirectorBuy5,100$3.91$19,941.00View SEC Filing  
11/18/2013Robert Greczyn, Jr.CEOBuy10,000$4.15$41,500.00View SEC Filing  
1/30/2013Buzz BensonDirectorBuy50,000$9.00$450,000.00View SEC Filing  
1/30/2013Three Arch Capital LpMajor ShareholderBuy215,000$9.00$1,935,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for LipoScience (NASDAQ:LPDX)
DateHeadline logoMiraculins: Pioneering a New Approach to Diabetes Screening (NASDAQ:LPDX) - January 27 at 8:00 AM logoUS STOCKS-Cantor turns bearish on U.S. equities (NASDAQ:LPDX) - September 25 at 10:27 AM


LipoScience (NASDAQ:LPDX) Chart for Wednesday, October, 26, 2016

Last Updated on 10/26/2016 by Staff